Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.53 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 8/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24464193 | 0.89 | ROCK2 (0.66) | ROCK2ROCK1ATRCDK2CCNE1 | |
| SCHEMBL21451348 | 0.89 | ROCK2 (0.67) | ROCK2ROCK1CDK2CCNE1 | |
| SCHEMBL24464163 | 0.88 | ROCK2 (0.53) | ROCK2ROCK1CDK2CCNE1IGF1R | |
| SCHEMBL24464148 | 0.87 | ROCK2 (0.53) | ROCK2ROCK1CDK2CCNE1 | |
| SCHEMBL24464173 | 0.83 | NPC1 (0.50) | ROCK2ROCK1 | |
| SCHEMBL24862335 | 0.82 | KDR (0.44) | ROCK2ROCK1 | |
| SCHEMBL24464147 | 0.80 | ROCK1 (0.57) | ROCK2ROCK1 | |
| SCHEMBL24464202 | 0.80 | ROCK2 (0.53) | ROCK2ROCK1ATR | |
| SCHEMBL17041185 | 0.80 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL19592078 | 0.79 | ROCK2 (0.66) | ROCK2ROCK1ATRCDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | ROCK2, KDR, FLT1 | ROCK2 1/4885ROCK1 5/4885ATR 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.